Arginine methyltransferases in normal and malignant hematopoiesis

Sarah M. Greenblatt, Fan Liu, Stephen D Nimer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Arginine methylation is an abundant covalent modification that regulates diverse cellular processes, including transcription, translation, DNA repair, and RNA processing. The enzymes that catalyze these marks are known as the protein arginine methyltransferases (PRMTs), and they can generate asymmetric dimethyl arginine (type I arginine methyltransferases), symmetric dimethylarginine (type II arginine methyltransferases), or monomethyarginine (type III arginine methyltransferases). The PRMTs are capable of modifying diverse substrates, from histone components to specific nuclear and cytoplasmic proteins. Additionally, the PRMTs can orchestrate chromatin remodeling by blocking the docking of other epigenetic modifying enzymes or by recruiting them to specific gene loci. In the hematopoietic system, PRMTs can regulate cell behavior, including the critical balance between stem cell self-renewal and differentiation, in at least two critical ways, via (i) the covalent modification of transcription factors and (ii) the regulation of histone modifications at promoters critical to cell fate determination. Given these important functions, it is not surprising that these processes are altered in hematopoietic malignancies, such as acute myeloid leukemia, where they promote increased self-renewal and impair hematopoietic stem and progenitor cell differentiation.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalExperimental Hematology
Volume44
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Protein-Arginine N-Methyltransferases
Hematopoiesis
Hematopoietic Stem Cells
Arginine
Histone Code
Hematopoietic System
Chromatin Assembly and Disassembly
Hematologic Neoplasms
Enzymes
Nuclear Proteins
Acute Myeloid Leukemia
Epigenomics
DNA Repair
Histones
Methylation
Cell Differentiation
Transcription Factors
RNA
human PRMT2 protein
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Arginine methyltransferases in normal and malignant hematopoiesis. / Greenblatt, Sarah M.; Liu, Fan; Nimer, Stephen D.

In: Experimental Hematology, Vol. 44, No. 6, 01.06.2016, p. 435-441.

Research output: Contribution to journalArticle

@article{70bd9660fe984b149296400fcbdbfdd7,
title = "Arginine methyltransferases in normal and malignant hematopoiesis",
abstract = "Arginine methylation is an abundant covalent modification that regulates diverse cellular processes, including transcription, translation, DNA repair, and RNA processing. The enzymes that catalyze these marks are known as the protein arginine methyltransferases (PRMTs), and they can generate asymmetric dimethyl arginine (type I arginine methyltransferases), symmetric dimethylarginine (type II arginine methyltransferases), or monomethyarginine (type III arginine methyltransferases). The PRMTs are capable of modifying diverse substrates, from histone components to specific nuclear and cytoplasmic proteins. Additionally, the PRMTs can orchestrate chromatin remodeling by blocking the docking of other epigenetic modifying enzymes or by recruiting them to specific gene loci. In the hematopoietic system, PRMTs can regulate cell behavior, including the critical balance between stem cell self-renewal and differentiation, in at least two critical ways, via (i) the covalent modification of transcription factors and (ii) the regulation of histone modifications at promoters critical to cell fate determination. Given these important functions, it is not surprising that these processes are altered in hematopoietic malignancies, such as acute myeloid leukemia, where they promote increased self-renewal and impair hematopoietic stem and progenitor cell differentiation.",
author = "Greenblatt, {Sarah M.} and Fan Liu and Nimer, {Stephen D}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.exphem.2016.03.009",
language = "English (US)",
volume = "44",
pages = "435--441",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Arginine methyltransferases in normal and malignant hematopoiesis

AU - Greenblatt, Sarah M.

AU - Liu, Fan

AU - Nimer, Stephen D

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Arginine methylation is an abundant covalent modification that regulates diverse cellular processes, including transcription, translation, DNA repair, and RNA processing. The enzymes that catalyze these marks are known as the protein arginine methyltransferases (PRMTs), and they can generate asymmetric dimethyl arginine (type I arginine methyltransferases), symmetric dimethylarginine (type II arginine methyltransferases), or monomethyarginine (type III arginine methyltransferases). The PRMTs are capable of modifying diverse substrates, from histone components to specific nuclear and cytoplasmic proteins. Additionally, the PRMTs can orchestrate chromatin remodeling by blocking the docking of other epigenetic modifying enzymes or by recruiting them to specific gene loci. In the hematopoietic system, PRMTs can regulate cell behavior, including the critical balance between stem cell self-renewal and differentiation, in at least two critical ways, via (i) the covalent modification of transcription factors and (ii) the regulation of histone modifications at promoters critical to cell fate determination. Given these important functions, it is not surprising that these processes are altered in hematopoietic malignancies, such as acute myeloid leukemia, where they promote increased self-renewal and impair hematopoietic stem and progenitor cell differentiation.

AB - Arginine methylation is an abundant covalent modification that regulates diverse cellular processes, including transcription, translation, DNA repair, and RNA processing. The enzymes that catalyze these marks are known as the protein arginine methyltransferases (PRMTs), and they can generate asymmetric dimethyl arginine (type I arginine methyltransferases), symmetric dimethylarginine (type II arginine methyltransferases), or monomethyarginine (type III arginine methyltransferases). The PRMTs are capable of modifying diverse substrates, from histone components to specific nuclear and cytoplasmic proteins. Additionally, the PRMTs can orchestrate chromatin remodeling by blocking the docking of other epigenetic modifying enzymes or by recruiting them to specific gene loci. In the hematopoietic system, PRMTs can regulate cell behavior, including the critical balance between stem cell self-renewal and differentiation, in at least two critical ways, via (i) the covalent modification of transcription factors and (ii) the regulation of histone modifications at promoters critical to cell fate determination. Given these important functions, it is not surprising that these processes are altered in hematopoietic malignancies, such as acute myeloid leukemia, where they promote increased self-renewal and impair hematopoietic stem and progenitor cell differentiation.

UR - http://www.scopus.com/inward/record.url?scp=84964957431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964957431&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2016.03.009

DO - 10.1016/j.exphem.2016.03.009

M3 - Article

VL - 44

SP - 435

EP - 441

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 6

ER -